Insider Monkey
Why Analysts Favor Kiniksa Pharmaceuticals (KNSA)
📈
AI Sentiment
Highly Positive
9/10
- Home
- KNSA
as of 12-22-2025 4:00pm EST
$43.52
+$0.19
+0.43%
Kiniksa Pharmaceuticals International PLC is a clinical-stage biopharmaceutical company focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. The company's clinical-stage product candidates include Rilonacept, abiprubart, and mavrilimumab.
Chart Type:
Time Range:
| Founded: | 2015 | Country: | United Kingdom |
| Employees: | N/A | City: | LONDON |
| Market Cap: | 2.6B | IPO Year: | 2018 |
| Target Price: | $51.33 | AVG Volume (30 days): | 399.9K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.47 | EPS Growth: | N/A |
| 52 Week Low/High: | $17.82 - $43.73 | Next Earning Date: | 10-28-2025 |
| Revenue: | $597,973,000 | Revenue Growth: | 55.68% |
| Revenue Growth (this year): | 62.63% | Revenue Growth (next year): | 29.93% |
AI-Powered KNSA Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 70.67%
70.67%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Kiniksa Pharmaceuticals Ltd. (KNSA)
Tessari Eben
Sell
CHIEF OPERATING OFFICER
KNSA Dec 15, 2025
Avg Cost/Share
$41.56
Shares
12,048
Total Value
$500,714.88
Owned After
16,666
SEC Form 4
Quart Barry D
Sell
Director
KNSA Dec 15, 2025
Avg Cost/Share
$41.51
Shares
20,129
Total Value
$835,554.79
Owned After
12,546
SEC Form 4
Ragosa Mark
Sell
CHIEF FINANCIAL OFFICER
KNSA Dec 8, 2025
Avg Cost/Share
$41.49
Shares
42,841
Total Value
$1,777,473.09
Owned After
31,086
SEC Form 4
Tessari Eben
Sell
CHIEF OPERATING OFFICER
KNSA Nov 26, 2025
Avg Cost/Share
$42.89
Shares
200
Total Value
$8,578.00
Owned After
16,666
SEC Form 4
Tessari Eben
Sell
CHIEF OPERATING OFFICER
KNSA Nov 17, 2025
Avg Cost/Share
$40.69
Shares
12,470
Total Value
$514,224.10
Owned After
16,666
Ragosa Mark
Sell
CHIEF FINANCIAL OFFICER
KNSA Nov 12, 2025
Avg Cost/Share
$40.94
Shares
19,900
Total Value
$814,706.00
Owned After
31,086
SEC Form 4
Paolini John F.
Sell
CHIEF MEDICAL OFFICER
KNSA Oct 31, 2025
Avg Cost/Share
$37.14
Shares
82,542
Total Value
$3,065,609.88
Owned After
61,324
SEC Form 4
Ragosa Mark
Sell
CHIEF FINANCIAL OFFICER
KNSA Oct 28, 2025
Avg Cost/Share
$41.00
Shares
100
Total Value
$4,100.00
Owned After
31,086
SEC Form 4
Patel Sanj K
Sell
CHAIRMAN & CEO
KNSA Oct 22, 2025
Avg Cost/Share
$38.83
Shares
97,390
Total Value
$3,781,653.70
Owned After
111,794
SEC Form 4
Patel Sanj K
Sell
CHAIRMAN & CEO
KNSA Oct 21, 2025
Avg Cost/Share
$38.77
Shares
39,331
Total Value
$1,524,862.87
Owned After
111,794
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Tessari Eben | KNSA | CHIEF OPERATING OFFICER | Dec 15, 2025 | Sell | $41.56 | 12,048 | $500,714.88 | 16,666 | |
| Quart Barry D | KNSA | Director | Dec 15, 2025 | Sell | $41.51 | 20,129 | $835,554.79 | 12,546 | |
| Ragosa Mark | KNSA | CHIEF FINANCIAL OFFICER | Dec 8, 2025 | Sell | $41.49 | 42,841 | $1,777,473.09 | 31,086 | |
| Tessari Eben | KNSA | CHIEF OPERATING OFFICER | Nov 26, 2025 | Sell | $42.89 | 200 | $8,578.00 | 16,666 | |
| Tessari Eben | KNSA | CHIEF OPERATING OFFICER | Nov 17, 2025 | Sell | $40.69 | 12,470 | $514,224.10 | 16,666 | |
| Ragosa Mark | KNSA | CHIEF FINANCIAL OFFICER | Nov 12, 2025 | Sell | $40.94 | 19,900 | $814,706.00 | 31,086 | |
| Paolini John F. | KNSA | CHIEF MEDICAL OFFICER | Oct 31, 2025 | Sell | $37.14 | 82,542 | $3,065,609.88 | 61,324 | |
| Ragosa Mark | KNSA | CHIEF FINANCIAL OFFICER | Oct 28, 2025 | Sell | $41.00 | 100 | $4,100.00 | 31,086 | |
| Patel Sanj K | KNSA | CHAIRMAN & CEO | Oct 22, 2025 | Sell | $38.83 | 97,390 | $3,781,653.70 | 111,794 | |
| Patel Sanj K | KNSA | CHAIRMAN & CEO | Oct 21, 2025 | Sell | $38.77 | 39,331 | $1,524,862.87 | 111,794 |
Latest Kiniksa Pharmaceuticals Ltd. News
KNSA Breaking Stock News: Dive into KNSA Ticker-Specific Updates for Smart Investing
Simply Wall St.
High Growth Tech Stocks To Watch In The US December 2025
📊
AI Sentiment
Positive
7/10
MT Newswires
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $500,715, According to a Recent SEC Filing
📉
AI Sentiment
Negative
3/10
MT Newswires
Kiniksa Pharmaceuticals International Insider Sold Shares Worth $835,555, According to a Recent SEC Filing
📉
AI Sentiment
Negative
3/10
Compare KNSA vs Leading Stocks
See how KNSA stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "KNSA Kiniksa Pharmaceuticals Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.